Skip to content

Comparison of recurrent biliary obstruction rate among combination of ERCP plus EUS-BD (CERES) in malignant hilar biliary obstruction versus combination of ERCP plus PTBD (CERP): A prospective randomized controlled trial

Comparison of recurrent biliary obstruction rate among combination of ERCP plus EUS-BD (CERES) in malignant hilar biliary obstruction versus combination of ERCP plus PTBD (CERP): A prospective randomized controlled trial

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220810003
Enrollment
40
Registered
2022-08-10
Start date
2022-08-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant hilar biliary obstruction Malignant hilar biliary obstruction, Hilar Cholangiocarcinoma, Klatskin Tumor, Perihilar Cholangiocarcinoma, Endosonography, Endoscopic Ultrasonography, ERCP, EUS, EUS-guided biliary drainage (EUS-BD), Combination of EUS and ERCP (CERES), Percutaneous biliary drainage (PTBD)

Interventions

Combined ERCP and EUS-BD for malignant hilar obstruction,Combined ERCP and PTBD for malignant hilar obstruction
Experimental Procedure/Surgery,Active Comparator Procedure/Surgery
Combined ERCP with EUS-BD,Combined ERCP with PTBD

Sponsors

Excellence Center For GI Endoscopy, King Chulalongkorn Memorial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients with unresectable malignant biliary hilar obstruction 2. Patients with indication for biliary drainage 3. Patients with good liver area of more than 80% 4. Patients with ECOG score 0-2 5. Patients with expected life expectancy of more than 3 months 6. Patients age 18-90 years 7. Patients who consent to protocol

Exclusion criteria

Exclusion criteria: 1. Patients with uncorrectable coagulopathy 2. Pregnant patients 3. Patients with marked ascites which interfere with interventions 4. Patients with non-malignant biliary hilar obstruction 5. Patients who can not follow-up longer than 6 months

Design outcomes

Primary

MeasureTime frame
Recurrent biliary obstruction 6 months Recurrence of obstructive jaundice and/or cholangitis due to stent occlusion or migration

Secondary

MeasureTime frame
Technical success rate Post-operation Technically success in placement of biliary stent (ERCP/EUS) or catheter (PTBD) as planned in the intended appropriate location, confrmed radiologically and/or endoscopically,Clinical success rate 4 weeks after biliary drainage Reduction in bilirubin by more than 50% of baseline at 2 weeks and/or TB less than 3 mg/dL at 4 weeks,Adverse events Post-operation until the end of follow-up period Graded as per the standard lexicon using American Society of Gastrointestinal Endoscopy criteria,Cost-effectiveness analysis Post-procedure after the end of follow-up period Cost-effectiveness analysis ,Quality of life Post-procedure after the end of follow-up period EORTC Quality of Life questionnaire

Countries

Thailand

Contacts

Public ContactPradermchai Kongkam

King Chulalongkorn Memorial Hospital

pkongkam@gmail.com0805575111

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026